Hospital Clinico San Borja Arriaran
About Hospital Clinico San Borja Arriaran
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Abbott Medical Devices
2
ETOP IBCSG Partners Foundation
2
Kirby Institute
2
Mannkind Corporation
2
MedImmune LLC
2
Agennix
1
Astellas Pharma Inc
1
Boehringer Ingelheim
1
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
1
Corcym S.r.l
1
Daiichi Sankyo, Inc.
1
Clinical Trials at Hospital Clinico San Borja Arriaran
During the past decade, Hospital Clinico San Borja Arriaran conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 8 clinical trials were completed, i.e. on
average, 88.9% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 3 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer
2000-11-01
2016-08-01
Completed
1,086
Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer
2001-11-01
2015-06-01
Completed
5,099
Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children
2004-11-01
2006-05-01
Completed
6,635
Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up
2006-02-01
2008-09-01
Completed
677
Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season
2006-04-01
2007-02-01
Completed
260
A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)
2006-07-01
2009-03-01
Completed
100
Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer
2007-08-01
2019-05-15
Completed
4,884
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Hospital Clinico San Borja Arriaran" #1 sponsor was "Abbott Medical Devices" with 2 trials, followed by "ETOP IBCSG Partners Foundation" with 2 trials
sponsored, "Kirby Institute" with 2 trials sponsored, "Mannkind Corporation" with 2 trials sponsored and "MedImmune LLC"
with 2 trials sponsored. Other sponsors include 6 different institutions and
companies that sponsored additional 16 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital Clinico San Borja Arriaran"
#1 collaborator was "Breast International Group" with 2 trials as a collaborator, "Abbott" with 1 trials as a collaborator, "Basilea Pharmaceutica International Ltd" with 1 trials as a collaborator, "ETOP IBCSG Partners Foundation" with 1 trials as a collaborator and "European Organisation for Research and Treatment of Cancer - EORTC" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were
collaborators in the rest 14 trials.
Clinical Trials Conditions at Hospital Clinico San Borja Arriaran
According to Clinical.Site data, the most researched conditions in "Hospital Clinico San Borja Arriaran" are
"Breast Cancer" (3 trials), "Stroke" (3 trials), "Aortic Valve Disease" (2 trials), "Atrial Fibrillation" (2 trials) and "Coronary Artery Disease" (2 trials). Many other conditions were trialed in "Hospital Clinico San Borja Arriaran" in a lesser frequency.
Clinical Trials Intervention Types at Hospital Clinico San Borja Arriaran
Most popular intervention types in "Hospital Clinico San Borja Arriaran" are "Drug" (14 trials), "Device" (3 trials), "Biological" (2 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "Paclitaxel" (2 trials), "2N(t)RTI" (1 trials), "70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)" (1 trials), "AMPLATZER™ LAA Occluder" (1 trials) and "Active comparator" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Hospital Clinico San Borja Arriaran
The vast majority of trials in "Hospital Clinico San Borja Arriaran" are
17 trials for "All" genders, 3 trials for "Female" genders and 1 trials for "Male" genders.
Clinical Trials Status at Hospital Clinico San Borja Arriaran
Currently, there are NaN active trials in "Hospital Clinico San Borja Arriaran".
undefined are not yet recruiting,
undefined are recruiting,
4 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 13 completed trials in Hospital Clinico San Borja Arriaran,
undefined suspended trials,
and 2 terminated clinical trials to date.
Out of the total trials that were conducted in Hospital Clinico San Borja Arriaran, 2 "Phase 1"
clinical trials were conducted, 4 "Phase 2" clinical
trials and 9 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 3 trials, and there were
also 2 trials that are defined as “Not Applicable".